Synapse - Hematology-Oncology Fellows

Results (1429)

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

The characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias

Meeting Abstract

Xie, Z.; Smith, A.; Komrokji, R. S.; Al Ali, N.; Patel, A. A.; Saygin, C.; Zeidan, A. M.; Bewersdorf, J. P.; Kishtagari, A.; Zeidner, J. F.; more...
Blood (2022)

Fulltext@MSK | Save

Systematic evaluation of AML-associated antigens identifies novel anti-U5 snRNP200 therapeutic antibodies for the treatment of AML

Meeting Abstract

Knorr, K.; Erickson, C.; Wang, E.; Rahman, J.; Mi, X.; Lu, S.; Fox, N.; Penson, A.; Hogg, S.; Stanley, R.; more...
Blood (2022)

Fulltext@MSK | Save

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders

Meeting Abstract

Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save

CNS relapse in T-cell lymphoma index: A risk score to predict central nervous system relapse in patients with T-cell lymphomas

Meeting Abstract

Bhansali, R. S.; Ellin, F.; Cao, M.; Relander, T.; Li, W.; Long, Q.; Ganesan, N.; Stuver, R.; Horwitz, S. M.; Wudhikarn, K.; more...
Blood (2022)

Fulltext@MSK | Save

Combined genetic ablation of CD54 and CD58 in car engineered cytotoxic lymphocytes effectively averts allogeneic immune cell rejection

Meeting Abstract

Hammer, Q.; Perica, K.; Mbofung, R. M.; van Ooijen, H.; Varady, E.; Jelcic, M.; Pan, Y.; Momayyezi, P.; Groff, B.; Abujarour, R.; more...
Blood (2022)

Fulltext@MSK | Save

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia

Meeting Abstract

Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M. F.; Stempel, J. M.; Stein, E.; Huntington, S. F.; Zeidan, A. M.
Blood (2022)

Fulltext@MSK | Save

Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study

Meeting Abstract

Qualls, D.; Buege, M. J.; Dao, P.; Caimi, P. F.; Rutherford, S. C.; Wehmeyer, G.; Romancik, J. T.; Leslie, L. A.; Merrill, M. H.; Crombie, J. L.; more...
Blood (2022)

Fulltext@MSK | Save

Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy

Meeting Abstract

Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
Blood (2022)

Fulltext@MSK | Save